Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer

Siang-Boon Koh, Leif W Ellisen

Research output: Contribution to journalArticle (Academic Journal)peer-review

8 Citations (Scopus)

Abstract

Immune checkpoint blockade plus chemotherapy is emerging as a standard treatment for some patients with triple-negative breast cancer (TNBC). In this issue of Cancer Cell, Zhang et al. employ extensive single-cell immune compartment analyses of pre- and post-therapy TNBC, and they reveal potential mechanisms of T cell activation and patterns of immune evolution that may inform future biomarkers of response and clinical benefit.

Original languageEnglish
Pages (from-to)1562-1564
Number of pages3
JournalCancer Cell
Volume39
Issue number12
Early online date8 Nov 2021
DOIs
Publication statusPublished - 13 Dec 2021

Bibliographical note

Publisher Copyright:
Copyright © 2021 Elsevier Inc. All rights reserved.

Fingerprint

Dive into the research topics of 'Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer'. Together they form a unique fingerprint.

Cite this